Nov. 2, 2023 -- Drug makers Seagen Inc. and Genmab A/S say Phase 3 trial results show a 30% drop in the“Patients with cervical cancer have few treatment options once their cancer comes back or spreads after initial treatment,” said Ignace B. Vergote, MD, co-founder of European Network of Gynaecological Oncological Trial groups and lead investigator in the clinical trial.
“The trial also measured the disease control rate, which is the percentage of patients who experience complete response, partial response or stable disease,” Fox News wrote. “TIVDAK displayed a 75.9% disease control rate, while chemo showed a 58.2% rate.”
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: